Study On The Mucosal Immunity Of Multi-Stage And Multi-Epitope DNA Vaccine Against Toxoplasma Gondii

In recent years, Toxoplasma gondii's vaccine has made great progress from the earliest dead vaccine to the late nucleic acid vaccine. Especially compound polyvalent vaccine and nucleic acid vaccine bring about new vitality and hope for Toxoplasma gondii's vaccine. Because complex intracellular parasites, such as T. gondii, present a plurality of antigenic epitopes and as the antigen presentation capability varies widely among different individuals, immunization with a vaccine that stimulates immunity to a broad array of antigens is likely to be more efficacious than immunization with a single antigen.In this study, we constructed an oral transgenic Salmonella typhimurium DNA vaccine expressing two major surface antigens or multi-epitope from T. gondii, and with or without the A2/B subunit of cholera toxin as a genetic adjuvant. The immunity induced by this vaccine in BALB/c mice and the protection afforded against challenge with the highly virulent RH strain of T.gondii is reported.The first part: To assess the protective immunity of BALB/c mice which were vaccinated via muscular with plasmid encoding T. gondii antigens SAG1, SAG2 with or without CTXA2/B gene. These genes were inserted into...